Angiotensin II blockade in kidney transplant recipients. - Wikidata - awgldk - TriplyDB

Angiotensin II blockade in kidney transplant recipients.

Angiotensin II blockade in kidney transplant recipients.

http://www.wikidata.org/entity/Q36574775

about

Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults Renin-angiotensin system blockade: Its contribution and controversy Cystatin C enhances glomerular filtration rate estimating equations in kidney transplant recipients.Daily fluid intake and outcomes in kidney recipients: post hoc analysis from the randomized ABCAN trial Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients.The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective Assessment and management of hypertension in transplant patients Expression of decoy receptor 3 in kidneys is associated with allograft survival after kidney transplant rejection Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: A meta-analysis of randomized controlled trials.Transplantation: The role of RAAS blockade in kidney transplantation Wnt/β-catenin signaling and renin-angiotensin system in chronic kidney disease.Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation.Renal lesions predict progression of diabetic nephropathy in type 1 diabetes The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.Hypertension after kidney transplantation: a pathophysiologic approach.Calcineurin inhibitors and hypertension: a role for pharmacogenetics?Renal allograft fibrosis: biology and therapeutic targets.The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.BP targets in renal transplant recipients: too high or too low?Transplant glomerulopathy: the view from the other side of the basement membrane.Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade.Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation.

P2860

Q24186372-1E9E0609-4955-4D18-BDDD-3BBEEA1DE626 Q26827221-BE141F68-EAFB-4459-A522-95E375F2EF0D Q33631221-9D0C41A9-17EE-4986-8EF6-7B3AA4A00E2F Q35175513-B01591BC-CEB3-4793-A450-DDB0BFE4A85D Q35653607-4F0C4409-9074-41F8-A5CA-A02205642A55 Q35658590-FC6ABE3E-8664-42BF-BD12-149270D0398A Q35658644-D567EF04-BA0D-452B-BC5B-E0DE8F47E840 Q36022635-6C09698C-A716-4D98-8BE1-CBA77AE5871D Q36276748-68FDD92F-F1DE-4D7D-A3EF-96BF854A7819 Q36599022-4CF1B42C-51F5-4C31-894D-9A5CDACF5774 Q36630037-C9967A95-DA2C-47AA-8664-C5B245622A0B Q36906370-7C09E869-F0B1-45FA-B269-FBF93767CABE Q36977349-94DB4AC1-65F4-4DE1-BDD4-CB4B87E7DDD8 Q37624685-5DEBC331-FBD1-46BB-A982-CF20694BCF5D Q38128162-CC470E47-A3AC-4757-87D8-1E6940288D6E Q38241677-6C0252BC-D28F-4CE3-A999-79403E441420 Q38359455-F98E0735-B632-4BFE-A761-2E01EB851B3E Q38585232-CB369AD5-4741-4490-BC03-BA38E022E4B9 Q42080953-6B23473B-F4C6-4706-B16A-3BC67C20B60D Q42712430-8A9F37C8-BFAA-4FA1-916B-601D3BA13339 Q42943160-982DE6AC-9B6F-44B8-B42F-92747A865D37 Q47107775-DA4E00A6-BC64-4F52-BE26-EF05898E1BDA Q48904824-B84CAE4D-DD26-4E43-829D-6699136FD0A0 Q53096709-E7A2060F-0B11-453F-AF60-DD2EA377E8EF

P2860

Angiotensin II blockade in kidney transplant recipients.

http://www.wikidata.org/entity/Q36574775

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Angiotensin II blockade in kidney transplant recipients.

@ast

Angiotensin II blockade in kidney transplant recipients.

@en

type

label

Angiotensin II blockade in kidney transplant recipients.

@ast

Angiotensin II blockade in kidney transplant recipients.

@en

prefLabel

Angiotensin II blockade in kidney transplant recipients.

@ast

Angiotensin II blockade in kidney transplant recipients.

@en

P1433

Q36574775-70190116-F220-493B-830F-46449D7F1E5F

P1476

Q36574775-2E96AAFF-613F-4D8A-ADF7-E7BFB9F194C7

P2093

Q36574775-1AC0E413-CCEB-47BD-B023-82C69B9BD1E7

Q36574775-20E26B4C-2552-47A5-AEF8-BEBAD938FEBB

Q36574775-22DFEF56-0D7F-4563-BD0B-AA47187A5EB4

Q36574775-30488F2D-256E-483D-AFC4-DE595367DD6D

Q36574775-32EB7E54-7ABD-44D5-BB60-4DC49ED28701

Q36574775-3E9CA6C0-5EA5-4847-9B1D-9C5C6F2EE475

Q36574775-4CD20DCF-6F29-4801-AE22-E5F5D1ADDC97

Q36574775-59D9F79A-4F2B-4398-B70B-D9391A65E869

Q36574775-59EE602B-FF5A-47AA-895B-B8A58F60513B

Q36574775-6298D664-DC92-4CDF-AE83-E21AC176E289

P2860

Q36574775-170EF4D7-DCCF-43E6-BE8B-1C3477DBB0D4

Q36574775-1D153223-19B9-434B-A28F-EA90A27924FD

Q36574775-24D02C7F-A616-4FAC-BD50-66C93A4331BB

Q36574775-27D73A2A-AE4C-44B6-BEC7-634A154B0389

Q36574775-2C15AC5A-D79F-4D6E-8358-21AAC239F23C

Q36574775-32213085-F85B-4633-BFEE-B86167AED8B7

Q36574775-4C463994-5E78-4AD4-8EA1-0703F80F4321

Q36574775-5B823481-97F8-4C7E-81DF-F514736A1600

Q36574775-93B2CEB7-6B66-4FBE-95B2-AC14F81D5F9A

Q36574775-C7C92713-6D9E-4E89-8D69-4504F9520CFE

P304

Q36574775-CD339AB5-814E-42DF-8772-D58230A4A98A

P31

Q36574775-86922434-B40B-4A8B-B987-2A3455363659

P356

Q36574775-E9418524-8594-49AE-B39B-8E47379184EB

P433

Q36574775-B2862DAC-64B3-4704-90A4-1B35AE25BC4A

P478

Q36574775-0C53DA4B-B661-41A1-B181-796E41485E9E

P577

Q36574775-B9D053D1-69B0-48D2-AE4E-9604A70E8A08

P698

Q36574775-95DC07E7-BC3E-4F1A-889A-E0903E71A2BA

P932

Q36574775-2A907C25-CEAD-4F61-888F-2D15A362CA57

P356

P1433

Journal of the American Society of Nephrology

P1476

Angiotensin II blockade in kidney transplant recipients.

@en

P2093

Ann West

http://www.w3.org/2001/XMLSchema#string

Arthur Matas

http://www.w3.org/2001/XMLSchema#string

Arthur Ney

http://www.w3.org/2001/XMLSchema#string

Behzad Najafian

http://www.w3.org/2001/XMLSchema#string

Bertram Kasiske

http://www.w3.org/2001/XMLSchema#string

Hassan N Ibrahim

http://www.w3.org/2001/XMLSchema#string

Jeffery Connaire

http://www.w3.org/2001/XMLSchema#string

Jenny Bodner

http://www.w3.org/2001/XMLSchema#string

Jensina Ericksen

http://www.w3.org/2001/XMLSchema#string

Michael Mauer

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of chronic kidney disease

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group.

Renal and retinal effects of enalapril and losartan in type 1 diabetes

Chronic allograft nephropathy: current concepts and future directions.

The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course.

Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides.

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.

The natural history of chronic allograft nephropathy.

Identifying specific causes of kidney allograft loss.

P304

320-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012080777

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23308016

http://www.w3.org/2001/XMLSchema#string

P932

3559488

http://www.w3.org/2001/XMLSchema#string